This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Highlights: Abbott Lab, Bio-Rad Lab and Hill-Rom Holdings
by Zacks Equity Research
Zacks Industry Outlook Highlights: Abbott Lab, Bio-Rad Lab and Hill-Rom Holdings
3 Stocks to Capitalize on the Buoyant Medical Products Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ABT, BIO and HRC are well-poised to gain from the prospects.
Abbott (ABT) Nutrition Sales Strong Amid Spike in COVID Cases
by Zacks Equity Research
Abbott (ABT) is registering strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp
The Zacks Analyst Blog Highlights: Tesla, Meta Platforms, Abbott Lab, Comcast and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tesla, Meta Platforms, Abbott Lab, Comcast and 3M
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $128.38, marking a +1.29% move from the previous day.
Top Analyst Reports for Tesla, Meta Platforms & Abbott Laboratories
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Meta Platforms, Inc. (FB), and Abbott Laboratories (ABT).
4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic
by Riya Anand
Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) owing to strong third-quarter results and bullish 2021 outlook.
Why Is Abbott (ABT) Up 2.1% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Introduces New Next-Generation Infant Formula
by Zacks Equity Research
Abbott's (ABT) Similac 360 Total Care contains five different HMOs, similar to human breast milk, to support the health and development of an infant.
Abbott (ABT) Scales to a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Diabetes Care and Diagnostics businesses is driving the top line for Abbott (ABT).
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Abbott (ABT) Aveir System Meets Primary Pivotal Trial Endpoints
by Zacks Equity Research
Abbott's (ABT) Aveir pacing system has the potential to advance treatment for patients who need a pacemaker but where physicians are concerned about more invasive surgery.
The Zacks Analyst Blog Highlights: Alibaba, Abbott Laboratories, T-Mobile, Anheuser-Busch and Boston Scientific Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, Abbott Laboratories, T-Mobile, Anheuser-Busch and Boston Scientific Corp
Top Analyst Reports for Alibaba, Abbott & T-Mobile US
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Abbott Laboratories (ABT), and T-Mobile US, Inc. (TMUS).
Why Abbott (ABT) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
LabCorp (LH) Q3 Earnings Surpass Estimates, 2021 View Up
by Zacks Equity Research
LabCorp's (LH) Q3 Diagnostics revenues get significantly impacted by drop in sales for COVID-19 testing.
4 Medical Products Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
CONMED's (CNMD) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
CONMED's (CNMD) third-quarter earnings reflect strong segmental performance.
West Pharmaceutical (WST) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter earnings reflect segmental strong performance.
Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect robust performance across all its business units.
Align Technology (ALGN) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Continued momentum in Invisalign Clear Aligners and iTero scanners sales volumes drove Align Technology's (ALGN) revenues during the third quarter.
Edwards Lifesciences (EW) Beats on Q3 Earnings, Gross Margin Up
by Zacks Equity Research
Strong sales growth across all four products group along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) third-quarter revenues.